

## RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY  
SYSTEMS  
BRANCH

RECEIVE

APR 25 2003

TECH CENTER 1600/

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/647,457B  
Source: 1600  
Date Processed by STIC: 4/21/03

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN ASSISTANCE: e-mail: robert.wax @ uspto.gov Telephone: 703-306-4119

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202  
EFFECTIVE MAY 1, 2003 (via USPS): Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry directly to:  
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7<sup>th</sup> Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202  
Or  
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/01/2003



1600

Does Not Comply  
Corrected Diskette Needed

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003

TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\I647457B.raw

3 <110> APPLICANT: Yeda Research and Development Company Ltd.  
 5 <120> TITLE OF INVENTION: ASSAY FOR THE DIAGNOSIS OF SCHIZOPHRENIA BASED ON A NEW  
 PEPTIDE  
 7 <130> FILE REFERENCE: 1276302  
 9 <140> CURRENT APPLICATION NUMBER: 09/647,457B  
 10 <141> CURRENT FILING DATE: 2000-09-29  
 12 <150> PRIOR APPLICATION NUMBER: PCT/IL99/00190  
 13 <151> PRIOR FILING DATE: 1999-09-29  
 15 <150> PRIOR APPLICATION NUMBER: 123925  
 16 <151> PRIOR FILING DATE: 1998-04-02  
 18 <160> NUMBER OF SEQ ID NOS: 15  
 20 <170> SOFTWARE: PatentIn version 3.1  
 22 <210> SEQ ID NO: 1  
 23 <211> LENGTH: 17  
 24 <212> TYPE: PRT  
 25 <213> ORGANISM: Unknown  
 27 <220> FEATURE:  
 28 <223> OTHER INFORMATION: an isolated peptide which binds antibodies.  
 30 <220> FEATURE:  
 31 <221> NAME/KEY: MISC\_FEATURE  
 32 <222> LOCATION: (1)..(17)  
 33 <223> OTHER INFORMATION: Xaa in position 1 may be (SGETEDTFIAD) (IAD) (AD), D or may be  
 absent;  
 34 Xaa in position 9 may be C, G, or P; Xaa in position 15 may be (AP)  
 35 , or (PA); Xaa in position 17 may be R, or may be absent.  
 38 <400> SEQUENCE: 1  
 W--> 40 Xaa Leu Val Val Gly Leu Cys Thr Xaa Gln Ile Lys Thr Gly Xaa Cys  
 41 1 5 10 15  
 44 Xaa  
 48 <210> SEQ ID NO: 2  
 49 <211> LENGTH: 28  
 50 <212> TYPE: PRT  
 51 <213> ORGANISM: Unknown  
 53 <220> FEATURE:  
 54 <223> OTHER INFORMATION: being the immunologically active epitope  
 56 <400> SEQUENCE: 2  
 58 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu  
 59 1 5 10 15  
 62 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg  
 63 20 25  
 66 <210> SEQ ID NO: 3  
 67 <211> LENGTH: 16  
 68 <212> TYPE: PRT  
 69 <213> ORGANISM: Unknown

Variable length —  
 pls. see error  
 summary sheet  
 item 5

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003

TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\I647457B.raw

72 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

73 levels in body fluids of schizophrenic patients.

75 <400> SEQUENCE: 3

77 Leu Val Val Gly Leu Cys Thr Cys Gln Ile Lys Thr Gly Pro Ala Cys

78 1 5 10 15

81 <210> SEQ ID NO: 4

82 <211> LENGTH: 20

83 <212> TYPE: PRT

84 <213> ORGANISM: Unknown

86 <220> FEATURE:

87 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

88 levels in body fluids of schizophrenic patients.

90 <400> SEQUENCE: 4

92 Ile Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly

93 1 5 10 15

96 Ala Pro Cys Arg

97 20

100 <210> SEQ ID NO: 5

101 <211> LENGTH: 19

102 <212> TYPE: PRT

103 <213> ORGANISM: Unknown

105 <220> FEATURE:

106 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

107 levels in body fluids of schizophrenic patients

109 <400> SEQUENCE: 5

111 Ala Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala

112 1 5 10 15

115 Pro Cys Arg

119 <210> SEQ ID NO: 6

120 <211> LENGTH: 18

121 <212> TYPE: PRT

122 <213> ORGANISM: Unknown

124 <220> FEATURE:

125 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

126 levels in body fluids of schizophrenic patients

128 <400> SEQUENCE: 6

130 Asp Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro

131 1 5 10 15

134 Cys Arg

138 <210> SEQ ID NO: 7

139 <211> LENGTH: 17

140 <212> TYPE: PRT

141 <213> ORGANISM: Unknown

143 <220> FEATURE:

144 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

145 levels in body fluids of schizophrenic patients

147 <400> SEQUENCE: 7

149 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003

TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\I647457B.raw

```

153 Arg
157 <210> SEQ ID NO: 8
158 <211> LENGTH: 17
159 <212> TYPE: PRT
160 <213> ORGANISM: Unknown
162 <220> FEATURE:
163 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
164      levels in body fluids of schizophrenic patients
166 <400> SEQUENCE: 8
168 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys
169 1          5          10          15
172 Arg
176 <210> SEQ ID NO: 9
177 <211> LENGTH: 17
178 <212> TYPE: PRT
179 <213> ORGANISM: Unknown
181 <220> FEATURE:
182 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
183      levels in body fluids of schizophrenic patients
185 <400> SEQUENCE: 9
187 Leu Val Val Gly Leu Cys Thr Pro Gln Ile Lys Thr Gly Pro Ala Cys
188 1          5          10          15
191 Arg
195 <210> SEQ ID NO: 10
196 <211> LENGTH: 20
197 <212> TYPE: PRT
198 <213> ORGANISM: Unknown
200 <220> FEATURE:
201 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
202      levels in body fluids of schizophrenic patients
204 <400> SEQUENCE: 10
206 Ser Gly Glu Thr Glu Asp Thr Phe Ile Ala Asp Leu Val Val Gly Leu
207 1          5          10          15
210 Cys Thr Gly Gln
211      20
214 <210> SEQ ID NO: 11
215 <211> LENGTH: 16
216 <212> TYPE: PRT
217 <213> ORGANISM: Unknown
219 <220> FEATURE:
220 <223> OTHER INFORMATION: peptide capable of binding antibodies that are found in
elevated
221      levels in body fluids of schizophrenic patients
223 <400> SEQUENCE: 11
225 Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg
226 1          5          10          15
229 <210> SEQ ID NO: 12
230 <211> LENGTH: 12
231 <212> TYPE: PRT
232 <213> ORGANISM: Unknown

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003

TIME: 15:22:38

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\I647457B.raw

234 &lt;220&gt; FEATURE:

235 &lt;223&gt; OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

236 levels in body fluids of schizophrenic patients

238 &lt;400&gt; SEQUENCE: 12

240 Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys Arg

241 1 5 10

244 &lt;210&gt; SEQ ID NO: 13

245 &lt;211&gt; LENGTH: 16

246 &lt;212&gt; TYPE: PRT

247 &lt;213&gt; ORGANISM: Unknown

249 &lt;220&gt; FEATURE:

250 &lt;223&gt; OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

251 levels in body fluids of schizophrenic patients

253 &lt;400&gt; SEQUENCE: 13

255 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro Cys

256 1 5 10 15

259 &lt;210&gt; SEQ ID NO: 14

260 &lt;211&gt; LENGTH: 15

261 &lt;212&gt; TYPE: PRT

262 &lt;213&gt; ORGANISM: Unknown

264 &lt;220&gt; FEATURE:

265 &lt;223&gt; OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

266 levels in body fluids of schizophrenic patients

268 &lt;400&gt; SEQUENCE: 14

270 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Ala Pro

271 1 5 10 15

274 &lt;210&gt; SEQ ID NO: 15

275 &lt;211&gt; LENGTH: 16

276 &lt;212&gt; TYPE: PRT

277 &lt;213&gt; ORGANISM: Unknown

279 &lt;220&gt; FEATURE:

280 &lt;223&gt; OTHER INFORMATION: peptide capable of binding antibodies that are found in elevated

281 levels in body fluids of schizophrenic patients

283 &lt;400&gt; SEQUENCE: 15

285 Leu Val Val Gly Leu Cys Thr Gly Gln Ile Lys Thr Gly Pro Ala Cys

286 1 5 10 15

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003  
TIME: 15:22:39

Input Set : A:\1276302.1.ST25.txt  
Output Set: N:\CRF4\04212003\I647457B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 1,9,15,17

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/647,457B

DATE: 04/21/2003

TIME: 15:22:39

Input Set : A:\1276302.1.ST25.txt

Output Set: N:\CRF4\04212003\I647457B.raw

L:40 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0  
M:341 Repeated in SeqNo=1